Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 5 institutions in 2 countries.
Si Jie TangMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.ORCID https://orcid.org/0000-0001-5136-7353
Shanthi GiriKaiser Permanente Sacramento California USA.
Nima PahlavanKaiser Permanente North Valley Roseville California USA.
Sophia H HanMira Loma High School Sacramento California USA.
Ellery R SantosMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.
Glenda EspinalMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.
Ramkumar AishworiyaMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.ORCID https://orcid.org/0000-0002-5749-1248
Andrea SchneiderMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.ORCID https://orcid.org/0000-0002-4674-7244
David HesslMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.
Susan M RiveraMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.
Randi J HagermanMedical Investigation of Neurodevelopmental Disorders (MIND) Institute University of California Davis Davis California USA.
University of California, Davis · USKaiser Permanente · USKaiser Permanente Roseville Medical Center · USNational University of Singapore · SGUniversity of Maryland, College Park · US
Funding
GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEONARD J. ABBEDUTO, Melissa Dawn Bauman · 2020 to 2026
$9.7M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01NS110100 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID R HESSL, Susan M Rivera · 2018 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Tophaceous gout of the nose in a male · full record | OpenQuestion